AU2008312464A1 - Novel therapeutic targets in bowel disease - Google Patents

Novel therapeutic targets in bowel disease Download PDF

Info

Publication number
AU2008312464A1
AU2008312464A1 AU2008312464A AU2008312464A AU2008312464A1 AU 2008312464 A1 AU2008312464 A1 AU 2008312464A1 AU 2008312464 A AU2008312464 A AU 2008312464A AU 2008312464 A AU2008312464 A AU 2008312464A AU 2008312464 A1 AU2008312464 A1 AU 2008312464A1
Authority
AU
Australia
Prior art keywords
pxr
gene
protein
fragment
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008312464A
Other languages
English (en)
Inventor
Frank J. Gonzalez
Lorin Johnson
Xiaochao Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Ltd
United States Department of Health and Human Services
Original Assignee
Salix Pharmaceuticals Ltd
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd, United States Department of Health and Human Services filed Critical Salix Pharmaceuticals Ltd
Publication of AU2008312464A1 publication Critical patent/AU2008312464A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008312464A 2007-10-17 2008-10-16 Novel therapeutic targets in bowel disease Abandoned AU2008312464A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99923407P 2007-10-17 2007-10-17
US60/999,234 2007-10-17
PCT/US2008/080115 WO2009052255A2 (en) 2007-10-17 2008-10-16 Novel therapeutic targets in bowel disease

Publications (1)

Publication Number Publication Date
AU2008312464A1 true AU2008312464A1 (en) 2009-04-23

Family

ID=40568065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008312464A Abandoned AU2008312464A1 (en) 2007-10-17 2008-10-16 Novel therapeutic targets in bowel disease

Country Status (7)

Country Link
US (1) US20110055943A1 (enExample)
EP (1) EP2201372A4 (enExample)
JP (1) JP2011501672A (enExample)
CN (1) CN101896815A (enExample)
AU (1) AU2008312464A1 (enExample)
MX (1) MX2010004333A (enExample)
WO (1) WO2009052255A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
HRP20140939T1 (hr) * 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
CN108267522A (zh) * 2017-12-28 2018-07-10 北京和合医学诊断技术股份有限公司 检测血液中奥氮平药物含量的液相色谱分析方法
CN110470771B (zh) * 2019-09-05 2021-06-01 清华大学 一种评价转基因植物食用安全性的方法
CN117031004B (zh) * 2023-08-09 2024-10-01 四川省医学科学院·四川省人民医院 一种检测网膜素-1的试剂在制备预测或评估ibs患者生活质量的产品中的应用

Also Published As

Publication number Publication date
MX2010004333A (es) 2010-11-30
US20110055943A1 (en) 2011-03-03
JP2011501672A (ja) 2011-01-13
CN101896815A (zh) 2010-11-24
WO2009052255A2 (en) 2009-04-23
EP2201372A2 (en) 2010-06-30
EP2201372A4 (en) 2010-11-10
WO2009052255A3 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
Shore et al. The therapeutic potential of orphan GPCRs, GPR35 and GPR55
Hopp et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
Xiong et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood–brain barrier for Aβ1–40 peptides
US6358698B1 (en) Methods of identifying inverse agonists of the serotonin 2A receptor
AU2025220689A1 (en) Hsd17b13 variants and uses thereof
Thoonen et al. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice
US20150065556A1 (en) Therapeutic targets for mitochondrial disorders
US20050148018A1 (en) Methods of identifying inverse agonists of the serotonin 2A receptor
Tanihata et al. Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition
Kelly et al. Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Gαs, a G-protein subunit genetically linked to schizophrenia
US20150240235A1 (en) Methods for producing a population of pancreatic beta-cells
US20110055943A1 (en) Novel therapeutic targets in inflammatory bowel disease
JP2023052057A (ja) リンパ系疾患の診断及び治療のための組成物及び方法
AU2012257731B2 (en) EphA4 is a disease modifier in motor neuron disease
Al Khazal et al. Unexpected obesity, rather than tumorigenesis, in a conditional mouse model of mitochondrial complex II deficiency
US12533362B2 (en) Methods for treating diseases associated with ciliopathies
US20050031605A1 (en) Compositions and methods of treating diabetes
JP6825910B2 (ja) Ｆｌａｔｔｏｐ（Ｆｌｔｐ）はβ細胞成熟についての新規のバイオマーカーである
Keller et al. What the BTBR/J mouse has taught us about diabetes and diabetic complications
US10220069B2 (en) Compositions and methods for treating diabetes
JP6868237B2 (ja) ヒトの薬物代謝酵素誘導及び薬物動態予測が可能な新規薬物代謝酵素誘導評価方法
US20060200870A1 (en) Methods of treating muscular dystrophy
WO1998032878A1 (en) Gene based assay for agents with potential therapeutic efficacy in the treatment of obsessive compulsive disorder and disorders related thereto
US12496301B2 (en) Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
Buqaileh The Role of Muscarinic Acetylcholine Receptor 3 in the Pathogenesis of Polycystic Kidney Disease

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period